Recce Pharmaceuticals Ltd
RCE
Rank in Stocks
#21089
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating... Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Share Price
$0.23880556
Last synced: 2026-11-10
Market Cap
$73.04M
Change (1 day)
0.00%
Change (1 year)
-15.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Recce Pharmaceuticals Ltd (RCE)
Category
Healthcare
EPS for Recce Pharmaceuticals Ltd (RCE)
EPS as of June 2026 TTM: $-0.04
According to Recce Pharmaceuticals Ltd's latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of $-0.06, an increase over its 2024 EPS of $-0.07.
EPS history for Recce Pharmaceuticals Ltd from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | -41.50% |
| 2025 | $-0.06 | -10.66% |
| 2024 | $-0.07 | 34.27% |
| 2023 | $-0.05 | 15.08% |
| 2022 | $-0.04 | -33.28% |
| 2021 | $-0.06 | 178.45% |
| 2020 | $-0.02 | 13.17% |
| 2019 | $-0.02 | 41.38% |
| 2018 | $-0.01 | -51.83% |
| 2017 | $-0.03 | -52.60% |
| 2016 | $-0.06 | 510.58% |
| 2015 | $-0.01 | -11.86% |
| 2014 | $-0.01 | -3.28% |
| 2013 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 2,435.61% |
US
|
|
| $15.66 | -44,715.38% |
US
|
|
| $-7.07 | 20,042.45% |
US
|
|
| $-5.29 | 14,971.23% |
AU
|
|
| $12.73 | -36,374.07% |
BE
|
Questions about Recce Pharmaceuticals Ltd's earnings per share (EPS)
What is Recce Pharmaceuticals Ltd's earnings per share (EPS)?
Recce Pharmaceuticals Ltd's earnings per share (EPS) over the last twelve months is $-0.04, as of Jun 2026.
What was Recce Pharmaceuticals Ltd's earnings per share (EPS) in 2025?
In 2025, Recce Pharmaceuticals Ltd's earnings per share (EPS) was $-0.06, compared with $-0.07 in 2024.
How has Recce Pharmaceuticals Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Recce Pharmaceuticals Ltd's earnings per share (EPS) was highest in 2020 ($-0.02) and lowest in 2024 ($-0.07).
How does Recce Pharmaceuticals Ltd's earnings per share (EPS) compare with similar companies?
Recce Pharmaceuticals Ltd's earnings per share (EPS) ($-0.04) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.